Savior Lifetec Corporation (TPEX:4167)

Market Cap	5.96B -5.2%
Revenue (ttm)	1.16B -7.9%
Net Income	495.76M +175.7%
EPS	1.57 +193.3%
Shares Out	310.44M
PE Ratio	12.26
Forward PE	n/a
Dividend	0.40 (2.05%)
Ex-Dividend Date	Jul 14, 2025

Volume	1,224,997
Average Volume	2,641,348
Open	19.20
Previous Close	19.20
Day's Range	18.75 - 19.20
52-Week Range	14.35 - 22.60
Beta	0.38
RSI	42.50
Earnings Date	Mar 13, 2026

About Savior Lifetec

Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, meropenem, and ertapenem products. The company was founded in 1993 and is headquartered in Tainan City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 384
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4167

Financial Performance

In 2024, Savior Lifetec's revenue was 1.22 billion, an increase of 15.91% compared to the previous year's 1.05 billion. Earnings were 182.38 million, an increase of 507.33%.